VerImmune is an immune oncology company focused on redirecting pre-existing memory from past infecti
Location: United States, Maryland, Baltimore
Employees: 1-10
Total raised: $10.1M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | SeedFolio | seedfolio.... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.09.2024 | Seed | $4.5M | - |
| 25.09.2023 | - | $3.1M | - |
| 05.08.2022 | Seed | $2.5M | - |
Mentions in press and media 18
| Date | Title | Description |
| 21.08.2025 | SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM | Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech st... |
| 28.09.2024 | VerImmune Secures $4.5 Million to Propel Innovative Cancer Immunotherapy | In the ever-evolving landscape of biotechnology, innovation is the lifeblood that fuels progress. VerImmune, a Bethesda-based company, has just taken a significant step forward by securing $4.5 million in the first closing of its Pre-Series... |
| 27.09.2024 | VerImmune: $4.5 Million (Pre-Series A) Secured To Develop Virus-Inspired Particle Platform | VerImmune, a venture-backed biotechnology company developing a Virus-inspired Particle (ViP) platform technology, announced the first closing of $4.5 million in its Pre-Series A funding round. The funding was led by Beiley Biofund, an early... |
| 24.09.2024 | VerImmune Closes $4.5M First Closing of Pre-Series A Financing | VerImmune, a Bethesda, MD-based biotechnology company developing virus-inspired particle (ViP™) platform technology, raised $4.5M in first closing of Pre-Series A funding. The round was led by Beiley Biofund. New investors, including Dr. Jo... |
| 18.07.2024 | PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Prog... | The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year Amgen and NSG BioLabs extended th... |
| 18.07.2024 | PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Prog... | The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year Amgen and NSG BioLabs extended th... |
| 17.07.2024 | PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts with Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem with Fourth Site and Extended Awards Prog... | The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year Amgen and NSG BioLabs extended th... |
| 25.09.2023 | Biotech startup VerImmune just raised $3.1M for its cancer therapy tech | In a follow-on round, a local biotech company raised millions to help with the development of its cancer prevention tech. VerImmune, a startup based out of Johnson & Johnson’s JLabs space in northwest DC, raised $3.1 million in a round ... |
| 20.09.2023 | VerImmune Raises Over $3M in Additional Funding | VerImmune, Inc., a Washington, DC-based early-stage biotechnology company specializing in the development of innovative products based on a novel Virus-inspired Particle (ViP™) technology platform, raised an additional $3.125million from fo... |
| 20.02.2023 | VerImmune, Inc. Announces Issuance of Second U.S Patent Protecting Proprietary Technology Platform | WASHINGTON (PRWEB) February 20, 2023 VerImmune, Inc. (“VerImmune”), a biotechnology company leading the way in developing virus-inspired particle modalities for cancer treatment, is proud to announce the issuance of its second U.S. Patent f... |
Show more